Skip to main content
NCBI home page
Molecular Pathology : MP logoLink to Molecular Pathology : MP
. 1999 Jun;52(3):135–139. doi: 10.1136/mp.52.3.135

Absence of prolactin gene expression in colorectal cancer.

A J Wood 1, C M Thomas 1, K R Baumforth 1, J R Flavell 1, K W Scott 1, R H Grace 1, J G Williams 1, M R Holland 1, R Dunn 1, A G Jacobs 1, A Harrison 1, S Brun 1, N Plessis 1, P G Murray 1
PMCID: PMC395687  PMID: 10621834

Abstract

AIMS: Previous studies documenting hyperprolactinaemia in patients with colorectal cancer have suggested that the tumour is the source of hormone production. The aim of this study was to determine the frequency of hyperprolactinaemia in patients with colorectal cancer before, during, and after surgery, and also to determine whether prolactin is produced by these tumours. METHODS: Serum prolactin concentrations were measured in 20 patients with colorectal cancer before, during, and after surgical resection of their tumours. Samples taken during surgery included peripheral venous blood and blood taken from the main veins draining the tumour. To determine whether the tumour was responsible for the production of prolactin in these patients, paraffin wax embedded sections of tumour specimens were subjected to immunohistochemistry and western blotting using a monoclonal antibody to prolactin. RESULTS: Five patients (three women, two men) had preoperative prolactin concentrations above the normal reference range, although this increase was of clinical importance in only two. After surgical resection of their tumours, prolactin concentrations remained high in both patients. All 20 patients had greatly raised prolactin values at the time of surgery, irrespective of whether this was measured in peripheral blood or in blood taken from veins draining the tumour. All 20 colorectal cancer tissue samples, including those with raised preoperative and/or postoperative prolactin concentrations, were negative for prolactin staining. Frozen tissue was also available in four cases. The absence of prolactin gene expression in these four tumours was confirmed both by repeat immunohistochemistry and by western blotting. A further 50 colorectal cancer cases examined by immunohistochemistry alone were also unreactive for prolactin. CONCLUSIONS: The results of this study suggest that serum prolactin concentrations may occasionally be raised in colorectal cancer patients, but that the tumour is not the source of hormone production.

Full Text

The Full Text of this article is available as a PDF (203.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benker G., Jaspers C., Häusler G., Reinwein D. Control of prolactin secretion. Klin Wochenschr. 1990 Dec 4;68(23):1157–1167. doi: 10.1007/BF01815271. [DOI] [PubMed] [Google Scholar]
  2. Bhatavdekar J. M., Patel D. D., Giri D. D., Karelia N. H., Vora H. H., Ghosh N., Shah N. G., Trivedi S. N., Balar D. B. Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. Br J Cancer. 1992 Nov;66(5):977–980. doi: 10.1038/bjc.1992.395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bhatavdekar J. M., Shah N. G., Balar D. B., Patel D. D., Bhaduri A., Trivedi S. N., Karelia N. H., Ghosh N., Shukla M. K., Giri D. D. Plasma prolactin as an indicator of disease progression in advanced breast cancer. Cancer. 1990 May 1;65(9):2028–2032. doi: 10.1002/1097-0142(19900501)65:9<2028::aid-cncr2820650924>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  4. Chakraborty A., Chakraborty N. G., Chattopadhyay U. Prolactin response of NK cells, but not of LAK cells, is deficient in patients with carcinoma of oral cavity and during aging. Int J Cancer. 1996 Mar 28;66(1):65–69. doi: 10.1002/(SICI)1097-0215(19960328)66:1<65::AID-IJC12>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  5. Crozier T. A., Müller J. E., Quittkat D., Sydow M., Wuttke W., Kettler D. Effect of anaesthesia on the cytokine responses to abdominal surgery. Br J Anaesth. 1994 Mar;72(3):280–285. doi: 10.1093/bja/72.3.280. [DOI] [PubMed] [Google Scholar]
  6. Gerli R., Rambotti P., Nicoletti I., Orlandi S., Migliorati G., Riccardi C. Reduced number of natural killer cells in patients with pathological hyperprolactinemia. Clin Exp Immunol. 1986 May;64(2):399–406. [PMC free article] [PubMed] [Google Scholar]
  7. Ilan Y., Sibirsky O., Livni N., Gofrit O., Barack V., Goldin E. Plasma and tumor prolactin in colorectal cancer patients. Dig Dis Sci. 1995 Sep;40(9):2010–2015. doi: 10.1007/BF02208671. [DOI] [PubMed] [Google Scholar]
  8. Matera L., Ciccarelli E., Cesano A., Veglia F., Miola C., Camanni F. Natural killer activity in hyperprolactinemic patients. Immunopharmacology. 1989 Sep-Oct;18(2):143–146. doi: 10.1016/0162-3109(89)90067-2. [DOI] [PubMed] [Google Scholar]
  9. Nagano M., Chastre E., Choquet A., Bara J., Gespach C., Kelly P. A. Expression of prolactin and growth hormone receptor genes and their isoforms in the gastrointestinal tract. Am J Physiol. 1995 Mar;268(3 Pt 1):G431–G442. doi: 10.1152/ajpgi.1995.268.3.G431. [DOI] [PubMed] [Google Scholar]
  10. O'Leary E., Hubbard K., Tormey W., Cunningham A. J. Laparoscopic cholecystectomy: haemodynamic and neuroendocrine responses after pneumoperitoneum and changes in position. Br J Anaesth. 1996 May;76(5):640–644. doi: 10.1093/bja/76.5.640. [DOI] [PubMed] [Google Scholar]
  11. Oberholtzer E., Contarini M., Veglia F., Cossarizza A., Franceschi C., Geuna M., Provinciali M., Di Stefano G., Sissom J., Brizzi M. F. Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors. Adv Neuroimmunol. 1996;6(3):233–247. doi: 10.1016/s0960-5428(96)00019-8. [DOI] [PubMed] [Google Scholar]
  12. Patel D. D., Bhatavdekar J. M., Ghosh N., Vora H. H., Karelia N. H., Shah N. G., Suthar T. P., Balar D. B., Trivedi C. R. Plasma prolactin in patients with colorectal cancer. Value in follow-up and as a prognosticator. Cancer. 1994 Feb 1;73(3):570–574. doi: 10.1002/1097-0142(19940201)73:3<570::aid-cncr2820730312>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  13. Provinciali M., Di Stefano G., Stronati S., Raffaeli W., Pari G., Fabris N. Role of prolactin in the modulation of NK and LAK cell activity after short- or long-term morphine administration in neoplastic patients. Int J Immunopharmacol. 1996 Oct;18(10):577–586. doi: 10.1016/s0192-0561(96)00059-8. [DOI] [PubMed] [Google Scholar]
  14. Reber A., Huber P. R., Ummenhofer W., Gürtler C. M., Zurschmiede C., Drewe J., Schneider M. General anaesthesia for surgery can influence circulating melatonin during daylight hours. Acta Anaesthesiol Scand. 1998 Oct;42(9):1050–1056. doi: 10.1111/j.1399-6576.1998.tb05375.x. [DOI] [PubMed] [Google Scholar]
  15. Vidaller A., Guadarrama F., Llorente L., Méndez J. B., Larrea F., Villa A. R., Alarcón-Segovia D. Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient. J Clin Immunol. 1992 May;12(3):210–215. doi: 10.1007/BF00918091. [DOI] [PubMed] [Google Scholar]

Articles from Molecular Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES